Certolizumab pegol Certolizumab; CDP870|cas:428863-50-7|西域试剂

Certolizumab pegol Certolizumab; CDP870,99.30%

产品编号：Bellancom-P9953| CAS NO：428863-50-7

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P9953	￥600.00	杭州北京（现货）
Bellancom-P9953	￥1200.00	杭州北京（现货）
Bellancom-P9953	￥1800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Certolizumab pegol Certolizumab; CDP870

产品介绍

Certolizumab pegol (Certolizumab) 是重组、聚乙二醇化、抗原结合片段的人源化单克隆抗体，可选择性靶向和中和肿瘤坏死因子-α (TNF-α)。 Certolizumab pegol 可用于类风湿关节炎和克罗恩病的研究。

生物活性

Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research.

体外研究

Certolizumab pegol (Certolizumab) neutralizes soluble TNFα with an IC₉₀ of 3 ng/mL.
Certolizumab pegol (0-100 μg/mL, 1 h) completely inhibits subsequent production of IL-1β in response to LPS at concentrations over 1μg/mL in human monocytes.
Certolizumab pegol does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC).
Certolizumab pegol does not induce apoptosis of activated human monocytes or peripheral blood lymphocytes (PBLs) or result in degranulation or loss of cell membrane integrity in polymorphonuclear cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Certolizumab pegol (Certolizumab) (10 μg; i.p.; single dose) reduces the severity of acute pancreatitis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Healthy Wistar Albino male rats weighing 180 to 200 g, acute edematous pancreatitis was induced via intraperitoneal injection of 80 μg/kg Cerulein (HY-A0190) (20 μg/kg, 4 times at 1-hour intervals)
Dosage:	10 μg
Administration:	Intraperitoneal administration, single dose
Result:	Significantly decreased the serum levels of amylase, lipase, and lactate dehydrogenase. Histopathological edema, hemorrhage, parenchymal necrosis, and infiltration scores were also decreased, along with a decrease in malondialdehyde, myeloperoxidase, TNF-α, and caspase-3 activities.

体内研究

Certolizumab pegol (Certolizumab) (10 μg; i.p.; single dose) reduces the severity of acute pancreatitis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Healthy Wistar Albino male rats weighing 180 to 200 g, acute edematous pancreatitis was induced via intraperitoneal injection of 80 μg/kg Cerulein (HY-A0190) (20 μg/kg, 4 times at 1-hour intervals)
Dosage:	10 μg
Administration:	Intraperitoneal administration, single dose
Result:	Significantly decreased the serum levels of amylase, lipase, and lactate dehydrogenase. Histopathological edema, hemorrhage, parenchymal necrosis, and infiltration scores were also decreased, along with a decrease in malondialdehyde, myeloperoxidase, TNF-α, and caspase-3 activities.